Preventable hospital admissions related to medication (HARM): Cost analysis of the HARM study
Authors:
- Patricia M.L.A. Van Den BemtPBPatricia M.L.A. Van Den Bemt
- J. Bart PoolmanJPJ. Bart Poolman
- Lennart J. StokerLSLennart J. Stoker
- Antoine C.G. EgbertsAEAntoine C.G. Egberts
- Maarten J. PostmaMPMaarten J. Postma
- 1 January 2011
- journal article
- research article
- Published by Elsevier in Value in Health
- Vol. 14 (1) , 34-40
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Direct medical costs of adverse events in Dutch hospitalsBMC Health Services Research, 2009
- Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective studyBMC Clinical Pharmacology, 2007
- Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ, 2004
- Adverse drug reactions in a South Indian hospital—their severity and cost involvedPharmacoepidemiology and Drug Safety, 2003
- Assessing the Economic Impact of Adverse Drug EffectsPharmacoEconomics, 2003
- Rate, type, and cost of adverse drug reactions in emergency department admissionsEuropean Journal of Internal Medicine, 2001
- Practical approach to determining costs and frequency of adverse drug events in a health care networkAmerican Journal of Health-System Pharmacy, 2001
- Frequency and cost of serious adverse drug reactions in a department of general medicineBritish Journal of Clinical Pharmacology, 1998
- The Costs of Adverse Drug Events in Hospitalized PatientsJAMA, 1997
- Direct medical costs of disease and gastrointestinal side effects during treatment for arthritisThe American Journal of Medicine, 1988